Background and aims
Naloxegol is a peripherally acting, µ-opioid receptor antagonist for treatment of opioid-induced constipation (OIC). The main objective of this prospective study was to analyze the quality of life (QoL) of patients with cancer with naloxegol.

Methods
An observational, one year of follow-up study was conducted in 16 Spanish centers. Adult patients with active oncological disease and under treatment with opioids for pain control were selected. OIC with inadequate response to laxative(s) was the main diagnosis. The patients received treatment with naloxegol according to clinical criteria. Efficacy was assessed measuring response rate and symptoms evolution by means of PAC-SYM questionnaire. QoL was assessed by PAC-QOL questionnaire.

Results
126 patients were included in the study (58.2% men, 61.3 average age). Types of tumor were lung (35.7%), breast (37.3%), prostate (15.5%), and gastrointestinal (11,1%). About 75.5% had metastases. At 12 weeks, 80% of the patients were responders to naloxegol 12.5 mg/day and 89.7% to 25 mg/day. 75% and 90.5% of patients were responders to 12.5 mg/day and 25 mg/day, respectively, without concomitant laxative treatment. Response rate differences by tumor were not observed. PAC-SYM and PAC-QOL improvements were significant and even greater in breast cancer compared to other cancers (p<0.05). Karnofsky was not affected and pain intensity decreased from EVA 4.8 to 3.2 (p<0.0001).

Conclusions
The results of this first real-world-data study confirm the efficacy and QoL of naloxegol for the treatment of OIC in patients with cancer. Naloxegol does not interfere with opioid treatment for pain control in oncologic patients.

ANALYSIS OF THE QUALITY OF LIFE OF NALOXEGOL IN A REAL-WORLD 12-WEEK FOLLOW-UP STUDY, IN PATIENTS WITH CANCER AND OPIOID-INDUCED CONSTIPATION WITH LAXATIVE-INADEQUATE RESPONSE